Close Menu

technology development

Michigan-based Advaita Bioinformatics wants to be a one-stop shop for proteomics, transcriptomics, and variant analysis, as well as internet omics search.

The company formerly known as TransMed Systems looks to bring "clarity and transparency" to the emerging field of precision oncology and in patient-trial matching.

University of Crete spinout Gnosis Data Analysis is adding AI capabilities to Indivumed's IndivuType multi-omics cancer research platform.

The two Netherlands-based firms will market their joint offering to pharmaceutical companies and others researching immune system-related diseases.

The companies will develop analytics tools and leverage the Syapse Learning Health Network in an effort to shorten the time to market for new cancer therapies.

Researchers in Nigeria are developing a handheld diagnostic device for identifying high-risk colorectal cancer patients in low-resource environments.

Startup AiLife Diagnostics is contributing its NGS analysis, interpretation, and reporting pipelines to BGI's $600 DNBseq WGS assay.

Symbolized by its first time exhibiting at HIMSS, Roche Diagnostics is using data to bridge the worlds of imaging, sequencing, diagnostics, drug discovery, and treatment.

The Genomics4RD platform is focused on data harmonization from research collaborations across Canada, but its developers are eyeing a future in the clinical market.

An affiliation with City of Hope, the advent of Illumina NovaSeq, and the availability of HPC flash storage have changed the nature of high-performance computing at TGen.

Pages

The chief executive of the National Health Service in England is to call for tumor-agnostic drugs to be "fast-tracked," according to the Times.

Researchers in Australia are sequencing the Wollemi pine tree to try to protect it from extinction, Australia's ABC News reports.

Computerworld ranks Illumina as one of the top midsize organizations to work at in IT.

In Genome Research this week: links between biological aging and mutations affecting epigenetic regulators; long-read sequencing-based strategy to map chromatin accessibility; and more.